news flash·2025-06-19 08:18Core Viewpoint - Xinhua Pharmaceutical (000756) has announced the completion of patient enrollment for the first case in the Phase II clinical trial of OAB-14, a dry suspension for the treatment of mild to moderate Alzheimer's disease in China [1] Group 1: Company Information - OAB-14 is a novel chemical structure innovation drug developed by Xinhua Pharmaceutical in collaboration with Shenyang Pharmaceutical University, possessing independent intellectual property rights [1] - The Phase II clinical trial for OAB-14 is being conducted in collaboration with Xuanwu Hospital of Capital Medical University and multiple centers across the country [1] - The first patient enrollment in the clinical trial was completed on June 19, 2025 [1] Group 2: Industry Context - OAB-14 is classified as a Class 1 innovative drug, indicating its potential significance in the pharmaceutical industry for treating Alzheimer's disease [1]